Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Performance

Shares of NASDAQ LPCN traded up $0.15 during mid-day trading on Friday, reaching $5.15. The company’s stock had a trading volume of 10,670 shares, compared to its average volume of 45,894. The stock has a 50-day moving average of $5.09 and a two-hundred day moving average of $5.63. The stock has a market capitalization of $27.54 million, a P/E ratio of -6.78 and a beta of 1.18. Lipocine has a 1-year low of $2.38 and a 1-year high of $11.79.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Analysts predict that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.